Detalles de la búsqueda
1.
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Blood
; 135(7): 491-504, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31805182
2.
Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.
Br J Haematol
; 175(2): 300-307, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27434823
3.
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease.
J Am Heart Assoc
; 13(4): e028957, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348778
4.
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
Lancet Haematol
; 11(1): e27-e37, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980924
5.
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Blood
; 116(26): 6101-5, 2010 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-20833980
6.
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials.
Thromb Haemost
; 122(9): 1573-1583, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35909257
7.
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.
Blood Adv
; 6(22): 5908-5923, 2022 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150047
8.
Outcome measures in interventional trials for prevention or treatment of venous thrombosis in the pediatric population.
Semin Thromb Hemost
; 37(7): 840-7, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22187408
9.
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
J Thromb Haemost
; 19(5): 1259-1270, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33636042
10.
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Lancet Haematol
; 8(1): e22-e33, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290737
11.
PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design.
Thromb Haemost
; 119(5): 844-853, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30861550
12.
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.
Thromb Haemost
; 118(9): 1625-1636, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30112751
13.
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
Res Pract Thromb Haemost
; 2(2): 347-356, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30046738
14.
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
Res Pract Thromb Haemost
; 2(3): 580-590, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30046763
15.
A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study.
Haematologica
; 92(2): 244-7, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17296576
16.
Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Haematologica
; 92(4): 554-7, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17488668
17.
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Thromb Haemost
; 117(11): 2168-2175, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202215
18.
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
Can J Kidney Health Dis
; 4: 2054358117690338, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28270931
19.
Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
Thromb Haemost
; 116(3): 461-71, 2016 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27357738
20.
Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.
Thromb Haemost
; 94(6): 1164-71, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16411388